<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03091725</url>
  </required_header>
  <id_info>
    <org_study_id>201612107</org_study_id>
    <secondary_id>UL1TR000448</secondary_id>
    <secondary_id>KL2TR000450</secondary_id>
    <nct_id>NCT03091725</nct_id>
  </id_info>
  <brief_title>A Role for FGF21 in Postprandial Nutrient Homeostasis After RYGB</brief_title>
  <official_title>A Role for FGF21 in Postprandial Nutrient Homeostasis After RYGB</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Advancing Translational Science (NCATS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bariatric surgery markedly improves glycemic control in persons with T2D. Roux-en-Y gastric
      bypass (RYGB) a procedure that bypasses the upper gastrointestinal (UGI) tract results in
      greater rates of diabetes resolution compared to methods that leave the UGI tract intact.
      Studies suggest that mechanisms beyond weight-loss account for the superiority of RYGB
      compared to other surgical methods. These weight-loss independent metabolic effects may
      involve increased postprandial production and release of nutrition- responsive hormones.
      Fibroblast growth factor 21 (FGF21) is a nutrition-adaptive hormone with the potential to
      alleviate symptoms of diabetes and obesity. Preliminary data therefore suggests that RYGB
      surgery may alter postprandial FGF21 regulation which could be important for achieving
      post-meal nutrient homeostasis. Therefore, the goal of this study is to test how nutrient
      content of the meal affects FGF21 concentrations before and after weight loss induced by RYGB
      or very low calorie diet (VLCD) therapy. The importance of FGF21 for for glucose, insulin,
      triglyceride and adipose tissue and muscle metabolism in these two groups will also be
      tested.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 25, 2017</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postprandial FGF21 plasma concentrations</measure>
    <time_frame>9 months</time_frame>
    <description>Concentrations of FGF21 protein will be measured in plasma after consuming a high glucose meal or a high fat meal, before and after surgery or low calorie diet.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>RYGB group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this group are scheduled to undergo Roux-en-Y gastric bypass surgery and will be assessed after 16-18% weight-loss</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VLCD Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in this group will participate in a very low-calorie diet intervention to obtain a 16-18% weight loss.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Roux-en-Y gastric bypass surgery</intervention_name>
    <description>A bariatric surgery procedure which will help individuals achieve 16-18% weight loss</description>
    <arm_group_label>RYGB group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Very low-calorie diet</intervention_name>
    <description>Subjects will meet with a dietitian over 4-6 months to lose 16-18% of their body weight.</description>
    <arm_group_label>VLCD Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Surgery Group (RYGB):

          -  Males and Females

          -  Scheduled for RYGB surgery

          -  Body Mass Index 35-55 kg/m²

          -  25-65 years of age

          -  Without Type II Diabetes

        VLCD group:

          -  Males and Females

          -  Body Mass Index 35-55 kg/m²

          -  25-65 years of age

          -  Without Type II Diabetes

        Exclusion Criteria:

        Surgery Group (RYGB):

          -  Regular use of tobacco products

          -  Previous intestinal resection

          -  Pregnant or breastfeeding

          -  Evidence of significant organ system dysfunction or disease other than obesity and T2D

          -  Use of any medication that might, in the opinion of the investigator, affect metabolic
             function

          -  Exercise &gt;= to 90 min per week

          -  use or past use of hormone replacement therapy within the past 6 months

        VLCD Group:

          -  Regular use of tobacco products

          -  Previous intestinal resection

          -  Pregnant or breastfeeding

          -  Evidence of significant organ system dysfunction or disease other than obesity and T2D

          -  Use of any medication that might, in the opinion of the investigator, affect metabolic
             function

          -  Exercise &gt;= to 90 min per week

          -  Use or past use of hormone replacement therapy within the past 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lydia-Ann Harris, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>314-362-8191</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Johanna Sonnenschein, BA</last_name>
    <phone>314-747-2627</phone>
    <email>j.sonnenschein@wustl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amy Skornia, MS, RD, LD</last_name>
    <phone>314-424-8006</phone>
    <email>askornia@dom.wustl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johanna Sonnenschein, BA</last_name>
      <phone>314-747-2627</phone>
      <email>j.sonnenschein@wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Richard Stein, PhD</last_name>
      <phone>314-286-0077</phone>
      <email>rstein@wustl.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2017</study_first_submitted>
  <study_first_submitted_qc>March 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2017</study_first_posted>
  <last_update_submitted>May 17, 2017</last_update_submitted>
  <last_update_submitted_qc>May 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Roux-en-Y gastric bypass (RYGB)</keyword>
  <keyword>Very low calorie diet</keyword>
  <keyword>Fibroblast growth factor 21 (FGF21)</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

